Eikon Therapeutics, Inc. Common Stock
EIKNNASDAQHealthcareBiotechnology
Previous close
$11.39
+$0.64 · +5.95%
EIKN company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
40
Expensive
Momentum
41
Neutral
Sentiment
44
Mixed
Risk resilience
42
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteEikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Roger Perlmutter
- Listed since
- Feb 5, 2026
- Employees
- 384
Market position
Day range
Current $11.39
52-week range
Current $11.39
- Open
- $10.87
- Previous close
- $10.75
- Volume
- 532.8K
- 1.44× average
- Average volume
- 370.88K
- Average daily volume
- Market cap
- 616.64M USD
- Beta
- 0.86
- Market reference 1
- 50-day average
- $10.2336
- +11.30% above average
- 200-day average
- $11.1081
- +2.54% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 964.5M USD
- P/E (TTM)
- -2.46×
- P/B (TTM)
- 1.32×
- P/S (TTM)
- 0×
- EV / EBITDA
- -3.22×
- Earnings yield
- -39.93%
- Free cash flow yield
- -28.97%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- 36.89%
- Return on assets
- -54.52%
- Return on invested capital
- -61.65%
Financial health
- Debt / equity
- 0.54×
- Current ratio
- 6.34×
Financial statements
| Metric (USD) | FY2025 |
|---|---|
| Cost of goods sold | 24.18M USD |
| Gross profit | −24.18M USD |
| Research and development | 250.32M USD |
| Selling, general, and administrative | 88.63M USD |
| Operating expenses | 314.77M USD |
| Interest income | 15.57M USD |
| Interest expense | 837K USD |
| Depreciation and amortization | 24.18M USD |
| Operating income | −338.95M USD |
| Net income | −324.25M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 0%
- 0 beats, 3 misses, 0 met estimates
- Average EPS surprise
- -242.98%
- 3 comparable reports
- Latest EPS result
- -1.63
- Estimate -1.58 · Miss by 3.16%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$5.00
56.10% downsideEIKN news
EIKN peers
ETFs holding EIKN
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI6.08M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM5.68M0.01%81.62B USD0.19%$299.96+0.77%
Vanguard Extended Market ETFVXF2.22M0.00%93.7B USD0.05%$245.53+0.82%
iShares Russell 2000 Growth ETFIWO1.51M0.01%15.16B USD0.24%$387.37+1.24%
Vanguard Russell 2000 ETFVTWO1.13M0.01%17.4B USD0.06%$121.25+0.74%
Schwab U.S. Small-Cap ETFSCHA1.07M0.00%23.1B USD0.03%$34.83+0.52%
iShares Micro-Cap ETFIWC811.68K0.05%1.53B USD0.60%$198.39+1.10%
ALPS Medical Breakthroughs ETFSBIO726.18K0.31%236.37M USD0.50%$69.11+0.80%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 6.08M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 5.68M
- Weight
- 0.01%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Extended Market ETFVXF- Market value
- 2.22M
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Russell 2000 Growth ETFIWO- Market value
- 1.51M
- Weight
- 0.01%
- AUM
- 15.16B USD
- Expense ratio
- 0.24%
- Price / 1D
- $387.37+1.24%
Vanguard Russell 2000 ETFVTWO- Market value
- 1.13M
- Weight
- 0.01%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 1.07M
- Weight
- 0.00%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.83+0.52%
iShares Micro-Cap ETFIWC- Market value
- 811.68K
- Weight
- 0.05%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $198.39+1.10%
ALPS Medical Breakthroughs ETFSBIO- Market value
- 726.18K
- Weight
- 0.31%
- AUM
- 236.37M USD
- Expense ratio
- 0.50%
- Price / 1D
- $69.11+0.80%
Continue in GoAI
Research EIKNresearch.disclaimer